{'fraction_non_alphanumeric': 0.02112676056338028, 'fraction_numerical': 0.018779342723004695, 'mean_word_length': 5.136690647482014, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[The efficacy of proxodolol in patients with stable arterial hypertension].

The new original Russian drug proxodolol having alpha- and beta-adrenoblocking activities in a ratio of 1:100 was examined at Stages I and II of clinical trials. The drug was given to 29 male patients aged 30-63 years who suffered from Stages I and II persistent hypertensive disease with a baseline diastolic blood pressure of >95 mm Hg. Proxodolol as 10- and 40-mg tablets was demonstrated to be an effective antihypertensive agent, its antihypertensive effects being revealed in acute and chronic uses. The drug was well tolerated by the patients, causing no significant adverse reactions. Further comprehensive comparative controlled studies of proxodolol including larger patient groups will define the contribution of the drug in long-term antihypertensive prophylaxis.